Haesook Teresa Kim

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C.

Leukemia. 2020 Nov 17. PMID: 33204012

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.

Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C.

Bone Marrow Transplant. 2020 Oct 12. PMID: 33041331

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Armand P, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Brown JR.

Blood Adv. 2020 Sep 08. 4(17):4113-4123. PMID: 32882002

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.

Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C.

Bone Marrow Transplant. 2020 Sep 08. PMID: 32895491

Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.

Divito SJ, Aasebø AT, Matos TR, Hsieh PC, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims H, Gedde-Dahl T, Hagerstrom M, Hilaire J, Lian JW, Milford EL, Pinkus GS, Ho VT, Soiffer RJ, Kim HT, Mihm MC, Ritz J, Guleria I, Cutler CS, Clark RA, Jahnsen FL, Kupper TS.

J Clin Invest. 2020 Sep 01. 130(9):4624-4636. PMID: 32516138

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR.

Blood Adv. 2020 Aug 25. 4(16):3977-3989. PMID: 32841336

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P.

Blood. 2020 Jun 11. 135(24):2182-2191. PMID: 32478814

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

Espada E, Cheng MP, Kim HT, Woolley AE, Avigan JI, Forcade E, Soares MVD, Lacerda JF, Nikiforow S, Gooptu M, Romee R, Alyea EP, Armand P, Cutler CS, Ho VT, Koreth J, Antin JH, Soiffer RJ, Marty FM, Ritz J.

Blood Adv. 2020 05 12. 4(9):1881-1893. PMID: 32374880

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.

Murdock HM, Kim HT, Hambley B, Vachhani P, Denlinger N, Gier SH, Cho C, Perales MA, Koreth J, Ho VT, Soiffer RJ, McCurdy SR, Carroll M, Vasu S, Wang ES, Gondek LP, Devine S, Alyea EP, Gibson CJ, Lindsley RC.

Blood. 2019 Nov 13. 134(Supplement_1):48. PMID: 31724009

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.

Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2020 03. 26(3):529-539. PMID: 31678537